Treatment of peripheral arterial disease (PAD) has not changed significantly in recent years, and the typically prescribed drug classes for the prevention of atherothrombotic events are awash with generic options. Merck & Co. launched Zontivity for PAD in 2014, but performance has been much lower than initially expected; Aralez Pharmaceuticals now has US rights to this product. PAD Treatment Algorithms presents insights into the treatment practices of a disease that holds huge market opportunity for an agent that significantly outperforms current treatment approaches.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed PAD patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed PAD patients?
- How have Zontivity and generic rosuvastatin been integrated into the treatment algorithm?
- What proportion of PAD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PAD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with PAD?